The company uses AI and emotional intelligence to tailor recommendations for chronically ill patients

Even before COVID, there was a growing trend towards empowering patients with devices and apps to manage their own health. You would no longer have to wait to see a doctor if someone was wrong; instead, your FitBit or Apple Watch could tell you immediately. That has only increased in the last 18 months, of course, and billions are being invested now Medicines, digital therapeutics, devices, wearables and services so that patients can take a more active role in managing their care.

While many would agree that this is a good development and improves outcomes for patients, it also brings its own challenges and problems.

One problem is that remote health demands more from the patient and can only be truly effective if patients “actually do what they need to do to meet their health programs,” said Yoni Nevo, CEO of Sweetch, a platform that personalizes Recommendations for patients with chronic conditions, including cardiometabolic and autoimmune diseases.

“The rapidly evolving era of remote health lacks that critical component: effective, ongoing relationships between actors in the health ecosystem and all those they serve at every step of their unique journey,” he said.

That’s the void that Sweetch wants to fill with artificial and emotional intelligence to create a “hyper-personalized engagement platform”. And now the company has another round of funding to build its engine announced $ 20 million Series A financing round on Monday, led by Entrée Capital, along with Tal Capital, Noaber, Kortex Ventures and FinTLV Ventures and existing investors Philips, OurCrowd and Qure Ventures.

Founded in 2013, the Israeli company uses an engine called JITAI, or just-in-time adaptive intervention, to transform millions of data points taken from smartphones, other connected devices, and user interactions with Sweetch to automatically adapt to each personality and behavior the individual.

Technology can identify each individual’s compliance pattern so it can tailor recommendations specifically for them and deliver them in the right tone, at the right time, and in the right context so they are more likely to stick to their health program.

“Sweetch is having a significant and sustained impact on patient compliance holistically across multiple dimensions of their chronic disease and comorbidities, delivering lasting health outcomes and improved health economics,” said Nevo.

The company’s customers are Pharmaceutical companies, medical device manufacturers, payers and healthcare providers. For example, the company works with Pharmaceutical companies to promote their drugs and medical devices; The company is providing a “digital molecule” designed to promote drug adherence, increase the effectiveness of medical treatment, and then collect data, with the ultimate goal of: Improving health outcomes and reducing costs for payers.

The company is currently in the process of creating a calculator that shows how compliance with treatment programs, including exercise, weight management, diet, and medication, can affect health outcomes and expenses.

Sweetch’s platform has been used in at least one clinical study conducted at the Department of Endocrinology, Diabetes and Metabolism at Johns Hopkins University. The aim of the study was to determine whether the Sweetch app works in combination with a digital body weight scale in adults with prediabetes. The results showed that the app achieved 86% retention and improved clinical outcomes for patients with early-stage diabetes, including lowering HbA1c levels.

With this new financing round, Sweetch has now raised a total of 30 million US dollars and plans to use the money for further global expansion.

The company is currently focused on North America; certain markets in Europe “that are advanced in their reimbursement policies compared to others,” said Nevo; and certain countries in Latin America that have “a very high percentage of patients with chronic diseases that can only be treated by fully automated and scalable solutions like Sweetch’s”.

It is also used to expand its AI and EI technologytreat more chronic diseases.

“We believe Healthtech will enable the delivery of increasingly scalable solutions to address key problems affecting both individual lives and the most important vulnerabilities of the healthcare ecosystem,” Nevo told me.

“We are addressing chronic illness at scale in a remote health age – enabling health ecosystem actors to build ongoing relationships with individuals with chronic illnesses and empower them to meet their micro-goals at every step of their health journey using Sweetch’s hyper-personalized platform . “

(Image source:


Please enter your comment!
Please enter your name here